Ladiratuzumab vedotin (ADC)

Catalog No.

DHG52999

Description

Ladiratuzumab vedotin is an ADC consisting of a LIV-1-directed antibody and Monomethyl auristatin E (MMAE) used for the study of breast cancer.

Species reactivity

Human

Clonality

Monoclonal

Target

LIV-1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SEC.

Purification

Purified by Ion Exchange Chromatography.

Applications

Research Grade Biosimilar

Form

Liquid

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

SGN-LIV1A

Clone ID

Ladiratuzumab vedotin

Importance of Physical Medicine and Rehabilitation in a Patient With Bilateral Lumbosacral Plexopathy Following the Course of Ladiratuzumab Vedotin for Breast Cancer: A Case Report., PMID:38161548

From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds., PMID:36160422

Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic., PMID:35267507

Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential., PMID:35171746

Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan., PMID:33089726

Document Download

Ladiratuzumab vedotin (ADC).pdf